<p>Abu Dhabi Investment Authority (ADIA) has entered into definitive agreements to invest $200 million for a 3% stake in Micro Life Sciences Pvt Ltd (Meril), a medical devices company based out of Vapi in Gujarat. This investment values Meril at an enterprise value of $6.6 billion.</p><p>The transaction is subject to regulatory approval by the Competition Commission of India (CCI). </p><p>Post this investment, Meril will be backed by two globally recognized investors, ADIA and Warburg Pincus, the company said in a statement.</p>.Meril receives nod from ICMR for its indigenous Covid-19 self-test kit.<p>Founded by the Bilakhia Group, Meril is a MedTech, with a focus on clinically advanced solutions across multiple specialties — including Cardiovascular, Structural Heart, Orthopaedics, Endo-surgery, In-vitro Diagnostics and Surgical Robotics.</p><p>Headquartered in Vapi, Meril operates globally certified manufacturing and R&D facilities, across a 100-acre sustainable MedTech campus. The company employs more than 13,000 people, has 35+ global subsidiaries, and serves healthcare systems in 150+ countries.</p><p>With a robust in-house global R&D ecosystem and a portfolio of 200+ technology platforms, Meril leads in global clinical research and education.</p><p>“This investment by ADIA reinforces confidence in Meril’s long term vision and global ambitions. This investment will enable us to accelerate growth, attract world-class talent, and further strengthen our RCD and clinical research efforts as we work towards improving the quality of human life through advanced healthcare solutions," said Sanjeev Bhatt, Senior Vice President – Strategy, Meril. </p>
<p>Abu Dhabi Investment Authority (ADIA) has entered into definitive agreements to invest $200 million for a 3% stake in Micro Life Sciences Pvt Ltd (Meril), a medical devices company based out of Vapi in Gujarat. This investment values Meril at an enterprise value of $6.6 billion.</p><p>The transaction is subject to regulatory approval by the Competition Commission of India (CCI). </p><p>Post this investment, Meril will be backed by two globally recognized investors, ADIA and Warburg Pincus, the company said in a statement.</p>.Meril receives nod from ICMR for its indigenous Covid-19 self-test kit.<p>Founded by the Bilakhia Group, Meril is a MedTech, with a focus on clinically advanced solutions across multiple specialties — including Cardiovascular, Structural Heart, Orthopaedics, Endo-surgery, In-vitro Diagnostics and Surgical Robotics.</p><p>Headquartered in Vapi, Meril operates globally certified manufacturing and R&D facilities, across a 100-acre sustainable MedTech campus. The company employs more than 13,000 people, has 35+ global subsidiaries, and serves healthcare systems in 150+ countries.</p><p>With a robust in-house global R&D ecosystem and a portfolio of 200+ technology platforms, Meril leads in global clinical research and education.</p><p>“This investment by ADIA reinforces confidence in Meril’s long term vision and global ambitions. This investment will enable us to accelerate growth, attract world-class talent, and further strengthen our RCD and clinical research efforts as we work towards improving the quality of human life through advanced healthcare solutions," said Sanjeev Bhatt, Senior Vice President – Strategy, Meril. </p>
